

Report from the Extraordinary General Meeting of Surgical Science Sweden AB (publ)

At the extraordinary general meeting in Surgical Science Sweden AB (publ), held on 16 August 2021, the following resolution was passed.

The extraordinary general meeting resolved, in accordance with the proposal by the board of directors, to approve the board of directors' resolution on a new share issue of 12,857,000 shares. The subscription price amounts to SEK 0.05 per share, corresponding to the quota value of the shares. The right to subscribe for the new shares shall, with deviation from the shareholder's pre-emption rights, only be granted to Pareto Securities AB acting as settlement bank in the issue and which subscribes for shares on behalf of a number of institutional investors. The rationale for deviating from the shareholders' pre-emptive rights is to enable a capital raise in a time- and cost-efficient manner for the financing of the company's acquisition of Simbionix USA Corp.

Approximately 79.2 per cent of the votes were represented at the extraordinary general meeting.

Gothenburg, Sweden, August 16, 2021
Surgical Science Sweden AB (publ)
The Board

The press release is available in the attachment or via

<https://surgicalscience.com/aktien/pressmeddelanden/>

For further information, please contact:

Gisli Hennermark, CEO
Tel: +46 70 420 83 00
gisli.hennermark@surgicalscience.com

Anna Ahlberg, CFO
Tel: +46 70 855 38 35
anna.ahlberg@surgicalscience.com

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

About Surgical Science Sweden AB (publ)

One of the biggest challenges within healthcare globally is how injuries during care can be reduced. Education and training are key, as a large part of the training today can be performed outside the operating room. Surgical Science is a world leader in the manufacture of virtual reality simulators for evidence-based laparoscopic and endoscopic training. The simulators enable surgeons and other medical specialists to train and improve their psychomotor skills and instrument handling before entering the operating room. In parallel with its own products, Surgical Science works with simulation solutions for medical technology companies that develop surgical instruments for clinical use, such as robotic surgery.

Surgical Science is headquartered in Gothenburg, Sweden and present in Stockholm, Sweden, as well as in Seattle, Washington, in the US. Through sales offices in the US, France, China, and UAE as well as a global network of distributors, Surgical Science maintains a presence in most markets around the world. Surgical Science Sweden AB (publ) is traded on Nasdaq First North Growth Market, with Erik Penser Bank as Certified Adviser (tel: +46 8-463 83 00, e-mail: certifiedadviser@penser.se).